Patents Assigned to Jiangsu Medolution Ltd.
  • Substituted quinolines and formulations thereof
    Patent number: 12017996
    Abstract: The present disclosure is directed to formulations of novel quinolines and their pharmaceutically acceptable salts, which are useful for the treatment of protein kinases mediated diseases and conditions. The compounds of this disclosure have a general Formula I wherein R10 to R14 and X are defined herein.
    Type: Grant
    Filed: May 10, 2022
    Date of Patent: June 25, 2024
    Assignee: Jiangsu Medolution Ltd
    Inventor: Dawei Zhang
  • Substituted pyrimidines useful as EGFR-T790M kinase inhibitors
    Patent number: 10167264
    Abstract: The present invention is directed to novel pyrimidines, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof. The compounds and compositions of the present invention have protein kinases inhibitory activities and are expected to be useful for the treatment of protein kinases and/or mutants mediated diseases and conditions.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: January 1, 2019
    Assignee: Jiangsu Medolution Ltd
    Inventor: Dawei Zhang
  • Substituted pyrazolopyrimidines as kinases inhibitors
    Patent number: 9694011
    Abstract: The present invention is directed to novel pyrazolopyrimidines such as compounds of Formula I, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof. The compounds and compositions of the present invention have protein kinases inhibitory activities against BTK and/or EGFR T790M and are useful for the treatment of protein kinases mediated diseases and conditions.
    Type: Grant
    Filed: May 21, 2014
    Date of Patent: July 4, 2017
    Assignee: Jiangsu Medolution Ltd
    Inventor: Dawei Zhang
  • SUBSTITUTED PYRAZOLOPYRIMIDINES AS KINASES INHIBITORS
    Publication number: 20160120868
    Abstract: The present invention is directed to novel pyrazolopyrimidines, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof. The compounds and compositions of the present invention have protein kinases inhibitory activities against BTK and/or EGFR T790M and are useful for the treatment of protein kinases mediated diseases and conditions.
    Type: Application
    Filed: May 21, 2014
    Publication date: May 5, 2016
    Applicant: Jiangsu Medolution Ltd.
    Inventor: Dawei ZHANG